Indivior Pharmaceuticals, Inc. Financing Cash Flow
Indivior Pharmaceuticals, Inc. (INDV) reported Financing Cash Flow of -$166.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-03
- Indivior Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$173.00M.
- Indivior Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $7.00M.
- Indivior Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$5.00M, a 112.50% decline year-over-year.
- Indivior Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$3.00M.
- Indivior Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2025 was -$30.00M.
- Indivior Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2024 was -$102.00M.
- Indivior Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2023 was -$64.00M.
- Indivior Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2022 was -$101.00M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$173.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$166.00M 10-Q · filed 2026-08-03 | -$171.00M derived: sum of 3 quarters · filed 2026-08-03 | -$174.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $7.00M 10-Q · filed 2026-04-30 | $2.00M derived: sum of 2 quarters · filed 2026-04-30 | -$1.00M derived: sum of 3 quarters · filed 2026-04-30 | -$6.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | -$5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$8.00M derived: sum of 2 quarters · filed 2026-02-26 | -$13.00M derived: sum of 3 quarters · filed 2026-08-03 | -$30.00M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$8.00M derived: sum of 2 quarters · filed 2026-08-03 | -$25.00M 10-Q · filed 2025-10-30 | $15.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | -$5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$22.00M 10-Q · filed 2026-08-03 | $18.00M derived: sum of 3 quarters · filed 2026-08-03 | -$33.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | -$17.00M 10-Q · filed 2026-04-30 | $23.00M derived: sum of 2 quarters · filed 2026-04-30 | -$28.00M derived: sum of 3 quarters · filed 2026-04-30 | -$63.00M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $40.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$11.00M derived: sum of 2 quarters · filed 2026-02-26 | -$46.00M derived: sum of 3 quarters · filed 2026-02-26 | -$102.00M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$51.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$86.00M derived: sum of 2 quarters · filed 2025-10-30 | -$142.00M 10-Q · filed 2025-10-30 | |
| 2024-06-30 | -$35.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$91.00M 10-Q · filed 2025-07-31 | ||
| 2024-03-31 | -$56.00M 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | -$64.00M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | -$101.00M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |